DonaldLeeDurdenMDPhD
Pediatric Hematology & Oncology • San Diego, CACancer Genetics/Cancer Risk Assessment
Professor Emeritus, Pediatrics, UCSD School of Medicine
Dr. Durden is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3010 Childrens Way
2west
San Diego, CA 92123Phone+1 858-966-5811Fax+1 858-309-6301
Summary
- Dr. Donald Durden is a pediatric hematologist/oncologist in La Jolla, CA and is affiliated with Rady Children's Hospital - San Diego. He received his medical degree from University of Miami Miller School of Medicine and has been in practice 32 years. He specializes in cancer genetics/cancer risk assessment and solid tumor/neuro-oncology experimental therapeutics and is experienced in asparaginase, pathologic neovascularization, phosphatidylinositol 3-kinases, phosphorylation, and signal transducing adaptor proteins. He is a physician scientist with over 25 years of continuous NIH RO1 grant funding involved heavily into in silico drug discovery and development around novel molecular targets which include kinase, immuno-oncologic and epigenetic targets from target discovery efforts ongoing in his laboratory over the past 20 years.
Education & Training
University of WashingtonFellowship, Pediatric Hematology/Oncology, 1988 - 1993- University of WashingtonResidency, Pediatrics, 1987 - 1988
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1985 - 1987
University of Miami Leonard M. Miller School of MedicineClass of 1985
University of Miami School of MedicinePhD, 1979 - 1983
University of South FloridaB.S., Microbiology and Zoology, 1971 - 1977
Certifications & Licensure
GA State Medical License Current
NE State Medical License 2018 - 2022
CA State Medical License 2010 - 2019- American Board of Pediatrics Pediatric Hematology-Oncology
- Pediatric Hematology-OncologyPediatric Hematology-Oncology
Awards, Honors, & Recognition
- Editorial Board Molecular Cancer Research AACR, 2009
- TME NIH Study Section NIH, 2002-2007
- Cancer Working Group USWNR, 2012
- Join now to see all
Clinical Trials
- A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors Start of enrollment: 2007 Apr 01
- A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas Start of enrollment: 2010 Aug 01
Publications & Presentations
PubMed
- 135 citationsPlasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectinChiho Isogai, Walter E. Laug, Hiroyuki Shimada, Paul Declerck, Monique F. Stins
Cancer Research. 2001-07-15 - 102 citationsPhase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies.Daruka Mahadevan, E. G. Chiorean, Wayne Harris, D. D. Von Hoff, A. Stejskal-Barnett
European Journal of Cancer. 2012-12-01 - 115 citationsIntegrins αvβ3 and αvβ5 Are Expressed by Endothelium of High-Risk Neuroblastoma and Their Inhibition Is Associated with Increased Endogenous CeramideAnat Erdreich-Epstein, Hiroyuki Shimada, Susan Groshen, Ming Liu, Leonid S. Metelitsa
Cancer Research. 2000-02-01
Press Mentions
Potential New Anti-Cancer Drug Class Inhibits Multiple Molecular TargetsFebruary 2nd, 2017
Potential New Drug Class Hits Multiple Cancer Cell Targets, Boosting Efficacy and SafetyFebruary 1st, 2017
Grant Support
- Development of dual inhibitor of PI3K/BRD4 for cancer therapeuticsNIH NCI2017–2022
- Role of PTEN and PI-3 kinase in medulloblastomagenesisNIH NCI2017–2022
- Overcoming BTK inhibitor resistance in B-cell malignanciesNIH NCI2019–2020
- Maximum MYC control using dual PI-3K/BRD4 inhibitorsNIH NCI2018–2020
- Phase I trial of dual PI-3K/BRD4 inhibitor SF1126 in hepatocellular carcinomaFDA2016–2020
- Vascular Targeted PAN PI-3 Kinase Inhibitor Prodrug, SF1126 For Glioma TherapyNational Cancer Institute2010–2012
- Role Of SYK And RAC2 In Regulation Of Hif1alpha And Neovascularization.National Heart, Lung, And Blood Institute2009–2010
- Role Of SYK And RAC2 In Regulation Of Hif1alpha And Neovascularization.National Heart, Lung, And Blood Institute2009
- Vascular Targeted PAN PI-3 Kinase Inhibitor Prodrug, SF1126 For Glioma TherapyNational Cancer Institute2009
- Vascular Targeted PAN Pi-3kinase Inhibitor Prodrug, SF1126 For Glioma Therapy.National Cancer Institute2008
- Pten/Aktp53 Signaling Axis In Tumor Induced AngiogenesisNational Cancer Institute2004–2006
- Pten/Aktp53 Signaling Axis In Tumor Induced AngiogenesisNational Cancer Institute2002–2003
- RAC2 In Integrin Macrophage FunctionNational Heart, Lung, And Blood Institute2002
- Vascular Endothelial Cell Integrins In AngiogenesisNational Cancer Institute2000–2002
- Phase II Study For Treatment Of Pediatric Brain TumorsNational Cancer Institute1999
- Phase II Study For Treatment Of Pediatric Brain TumorsNational Cancer Institute1997–1998
Industry Relationships
- Founder, SignalRx Pharmaceuticals Inc.Founder drug discovery group combinatorial in silico drug discovery multiple targets kinase, epigenetic and immuno-oncologic in natureDisclosure: Shareholder in this private company2012 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
